



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 13:27
Last Report Issued 08/31/2017 09:53

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 4240SP-POS
Patient ID 4240SP-POS
Chain 17001645
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 17001645
Received 08/31/2017 09:38

Sample ID 17001645-001
Matrix Serum or Plasma
Patient Name 4240SP-POS
Patient ID 4240SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

4240SP Sufentanil, Serum/Plasma

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Sufentanil	50	ng/mL	0.10	
------------	----	-------	------	--

Synonym(s): Sufenta®

Following I.V. administration of 30 mcg Sufentanil/kg for surgical analgesia, mean peak plasma levels range from 36 - 43 ng/mL and decline to 0.33 ng/mL at 23 hours.

Terminal plasma elimination half-life (average = 2.7 hours) occurs at 2 hours post dose. Reported analgesic range: 0.05 - 0.3 ng/mL.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.